<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="//www.gellc.es/wp-content/plugins/wordpress-seo/css/main-sitemap.xsl"?>
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd http://www.google.com/schemas/sitemap-image/1.1 http://www.google.com/schemas/sitemap-image/1.1/sitemap-image.xsd" xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">
	<url>
		<loc>https://www.gellc.es/investigacion/ensayos-clinicos/</loc>
		<lastmod>2026-03-06T09:56:29+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.gellc.es/investigacion/ensayos-clinicos/estudio-en-llc-llp-sin-tratamiento-previo-zanubrutinib-obinutuzumab/</loc>
		<lastmod>2026-02-13T08:38:36+00:00</lastmod>
		<image:image>
			<image:loc>https://www.gellc.es/wp-content/uploads/2026/01/35148c73-fdb1-4b82-918d-a939b7288019.jpg</image:loc>
		</image:image>
	</url>
	<url>
		<loc>https://www.gellc.es/investigacion/ensayos-clinicos/ensayo-con-mosunetuzumab-chop-en-sindrome-de-richter-sin-tratamiento-previo/</loc>
		<lastmod>2026-03-06T09:56:29+00:00</lastmod>
		<image:image>
			<image:loc>https://www.gellc.es/wp-content/uploads/2026/01/Generated_Image_September_10_2025_-_6_05PM.jpg</image:loc>
		</image:image>
	</url>
</urlset>
<!-- XML Sitemap generated by Yoast SEO -->